Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity

Biochemical Pharmacology

Volumn 83, Issue 12, 2012, Pages 1674-1681

  Steri, Ramona ^a   Achenbach, Janosch ^a   Steinhilber, Dieter ^a   Schubert Zsilavecz, Manfred ^a   Proschak, Ewgenij ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Antidiabetic compounds; Drug repurposing; Farnesoid X receptor; Imatinib; Self organizing maps; Virtual screening

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ATORVASTATIN; ATOVAQUONE; CLOMIFENE; DOBUTAMINE; EZETIMIBE; FENOTEROL; FLUINDOSTATIN; FORMOTEROL; IMATINIB; KETOCONAZOLE; LABETALOL; MONTELUKAST; NICERGOLINE; PAPAVERINE; PAROXETINE; PENTAMIDINE; PODOPHYLLOTOXIN; PRANLUKAST; PROBUCOL; RALOXIFENE; RIMONABANT; RITODRINE; ROTIGOTINE; SORAFENIB; TAMOXIFEN; TAMSULOSIN; TELMISARTAN; UNINDEXED DRUG; ZAFIRLUKAST; ZIPRASIDONE;

ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; ASTHMA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONDYLOMA ACUMINATUM; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA BASE; DEPRESSION; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DYSLIPIDEMIA; GASTROINTESTINAL STROMAL TUMOR; HEART FAILURE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPOTENCE; INFERTILITY; KIDNEY CARCINOMA; MALARIA; OBESITY; OSTEOPOROSIS; PARKINSON DISEASE; PNEUMONIA; PREMATURE LABOR; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCHIZOPHRENIA; SYSTEMIC MYCOSIS; VASCULAR DISEASE; VASOSPASM;

BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; DRUG DISCOVERY; GLUCOSE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; PIPERAZINES; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTIONAL ACTIVATION;

EID: 84860125573     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.02.027     Document Type: Article

References (38)

1. T.N. Raju The Nobel chronicles Lancet 356 2000 346
2. C.G. Wermuth Selective optimization of side activities: the SOSA approach Drug Discov Today 11 2006 160 164
3. M. Patlak New Weapons to combat an ancient disease: treating diabetes FASEB J 16 2002 1853
4. S. Fiorucci, G. Rizzo, A. Donini, E. Distrutti, and L. Santucci Targeting farnesoid X receptor for liver and metabolic disorders Trends Mol Med 13 2007 298 309
5. T. Claudel, B. Staels, and F. Kuipers The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism Arterioscler Thromb Vasc Biol 25 2005 2020 2030
6. T. Kohonen Self-organized formation of topologically correct feature maps Biol Cybern 43 1982 59 69
7. P. Schneider, Y. Tanrikulu, and G. Schneider Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing Curr Med Chem 16 2009 258 266
8. M.A. Johnson, and G.M. Maggiora Concepts and applications of molecular similarity 1990 John Wiley & Sons New York
9. D.S. Wishart, C. Knox, A.C. Guo, D. Cheng, S. Shrivastava, and D. Tzur DrugBank: a knowledge base for drugs, drug actions and drug targets Nucleic Acids Res 36 2008 D901 D906
10. A. Gaulton, L.J. Bellis, A.P. Bento, J. Chambers, M. Davies, and A. Hersey ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res 40 2012 D1100 D1107
11. G. Schneider, W. Neidhart, T. Giller, and G. Schmid "Scaffold- hopping" by topological pharmacophore search: a contribution to virtual screening Angew Chem Int Ed 38 1999 2894 2896
12. S. Seuter, S. Väisänen, O. Rdmark, C. Carlberg, and D. Steinhilber Functional characterization of vitamin D responding regions in the human 5-lipoxygenase gene Biochim Biophys Acta 1771 2007 864 872
13. H. Wang, J. Chen, K. Hollister, L.C. Sowers, and B.M. Forman Endogenous bile acids are ligands for the nuclear receptor FXR/BAR Mol Cell 3 5 1999 543 553
14. M. Abdollahi, T.S. Chan, V. Subrahmanyam, and P.J. OBrien Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin Mol Cell Biochem 252 2003 205 211
15. S. Ge, G. Zhou, S. Cheng, D. Liu, J. Xu, and G. Xu Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model Atherosclerosis 205 2009 74 79
16. S. El-Swefy, and S.I. Hassanen Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats Ann Hepatol 8 2009 41 49
17. D. Veneri, M. Franchini, and E. Bonora Imatinib and regression of type 2 diabetes N Engl J Med 352 2005 1049 1050
18. R. Hägerkvist, L. Jansson, and N. Welsh Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet Clin Sci (Lond) 114 1 2008 65 71
19. M.S. Han, K.W. Chung, H.G. Cheon, S.D. Rhee, C.H. Yoon, and M.K. Lee Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice Diabetes 58 2009 329 336
20. M. Lassila, T.J. Allen, Z. Cao, V. Thallas, K.A. Jandeleit-Dahm, and R. Candido Imatinib attenuates diabetes-associated atherosclerosis Arterioscler Thromb Vasc Biol 24 2004 935 942
21. N. Agostino, V.M. Chinchilli, C.J. Lynch, A. Koszyk-Szewczyk, R. Gingrich, and J. Sivik Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice J Oncol Pharm Pract 17 2011 197 202
22. M. Breccia, M. Muscaritoli, Z. Aversa, F. Mandelli, and G. Alimena Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment J Clin Oncol 22 2004 4653 4655
23. A. Tsapas, E. Vlachaki, and M. Sarigianni Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML) Leukemia 32 2008 674 675
24. D. Mokhtari, and N. Welsh Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes Clin Sci (Lond) 118 2010 241 247
25. P.J. Little, N. Cohen, and G. Morahan Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes ScientificWorldJournal 9 2009 224 228
26. M. von Mehren, and N. Widmer Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing Cancer Treat Rev 37 2011 291 299
27. S. Renner, and G. Schneider Scaffold-hopping potential of ligand-based similarity concepts ChemMedChem 1 2006 181 185
28. M. Downes, M.A. Verdecia, A.J. Roecker, R. Hughes, J.B. Hogenesch, and H.R. Kast-Woelbern A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR Mol Cell 11 2003 1079 1092
29. D. Schuster, P. Markt, U. Grienke, J. Mihaly-Bison, M. Binder, and S.M. Noha Pharmacophore-based discovery of FXR agonists. Part I: model development and experimental validation Bioorg Med Chem 19 2011 7168 7180
30. S.M. Soisson, G. Parthasarathy, A.D. Adams, S. Sahoo, A. Sitlani, and C. Sparrow Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation Proc Natl Acad Sci USA 105 2008 5337 5342
31. R. Steri, M. Kara, E. Proschak, D. Steinhilber, G. Schneider, and M. Schubert-Zsilavecz Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription Future Med Chem 2 2010 575 586
32. H.G.F. Richter, G.M. Benson, K.H. Bleicher, D. Blum, E. Chaput, and N. Clemann Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties Bioorg Med Chem Lett 21 2011 1134 1140
33. M. Watanabe, Y. Horai, S.M. Houten, K. Morimoto, T. Sugizaki, and E. Arita Lowering bile acid pool size with a synthetic FXR agonist induces obesity and diabetes through reduced energy expenditure J Biol Chem 286 2011 26913 26920
34. B.S. Katzenellenbogen, and J.A. Katzenellenbogen Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta - regulation by selective estrogen receptor modulators and importance in breast cancer Breast Cancer Res 2 2000 335 344
35. T. Allen, F. Zhang, S.A. Moodie, L.E. Clemens, A. Smith, and F. Gregoire Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity Diabetes 55 2006 2523 2533
36. P.B. Watkins Insight into hepatotoxicity: the troglitazone experience Hepatology 41 2005 229 230
37. S.E. Nissen, and K. Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch Intern Med 170 2010 1191 1201
38. R. Steri, P. Schneider, A. Klenner, M. Rupp, J.M. Kriegl, and M. Schubert-Zsilavecz Target Profile Prediction: Cross-Activation of Peroxisome Proliferator-Activated Receptor (PPAR) and Farnesoid X Receptor (FXR) Mol Inform 29 2010 287 292